You are here: Industry Insights > Onvansertib

News List

Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in AML americanpharmaceuticalreview
December 11, 2019
Trovagene announced new in-vitro and in-vivo data suggesting that onvansertib may provide a new therapeutic option for patients who develop resistance to frontline treatment with venetoclax.
Trovagene Announces Patent for Combination of Onvansertib with Anti-Androgen Drugs americanpharmaceuticalreview
January 24, 2019
Trovagene announced the issuance of a new patent (10,155,006), entitled Combination Therapies and Methods of Use Thereof for Treating Cancer....
Trovagene Completes Dosing of Patients Treated with Onvansertib, Decitabine in AML Trial americanpharmaceuticalreview
September 28, 2018
Trovagene announced completion of the second dosing cohort of Onvansertib, its first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) Inhibitor, in combination with standard-of-care decitabine, in its Phase 1b/2 clinical trial in
European Commission Grants Orphan Drug Designation to Onvansertib americanpharmaceuticalreview
August 30, 2018
Trovagene announced the European Commission (EC) has endorsed the positive opinion of the Committee for Orphan Medicinal Products (COMP) and has granted Orphan Drug Designation (ODD) for Onvansertib, a first-in-class, 3rd generation, oral and highly-selec
Trovagene Receives USAN Approval for Onvansertib americanpharmaceuticalreview
August 16, 2018
Trovagene announced the United States Adopted Name (USAN) Council has approved Onvansertib as the nonproprietary (generic) name for its drug candidate.....